Genetic Association with Aggressive Prostate Cancer Discovered
Press release courtesy of Sinai Health System
March 16, 2017 (Toronto) – A study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cancer. The study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation. The frequency of the gene variants varied from 6 to 14% of the population of men with prostate cancer.
Prostate Cancer Canada Partners with Screw Cancer™
TORONTO, ON - Starting today, you can screw cancer and give hope in your local community by
purchasing the Screw Cancer™ screwdriver in support of Prostate Cancer Canada. The Screw Cancer™
campaign is partnering with Prostate Cancer Canada, as well as the Sunnybrook Hospital Foundation
(Toronto, ON), the Juravinski Hospital and Cancer Centre Foundation (Hamilton, ON) , the Thunder Bay
Regional Health Sciences Foundation, the Northern Cancer Foundation (Sudbury, ON) and the Grand
River Hospital Foundation (Kitchener-Waterloo, ON) to raise funds for research into improved
diagnostics and treatments, as well as support services and resources at the community level. The
campaign is designed to give you, the donor, the power to choose which local support organization
your donation will support when you purchase a screwdriver to #screwcancer.
Scientists identify DNA signature linked to prostate cancer severity
January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.
BRCA2 gene implicated in rare but lethal prostate cancer
January 9, 2017 – TORONTO, ON – Canadian scientists have discovered a link between an inherited mutation in the BRCA2 gene and a deadly form of prostate cancer. Funded by Prostate Cancer Canada and led by Dr. Robert Bristow of the Princess Margaret Cancer Centre in Toronto, the findings were published today in Nature Communications:
Thank You to our Canadian Mo Bros and Sistas!
TORONTO, December 1, 2016 - Prostate Cancer Canada congratulates the more than 500,000 Mo Bros and Mo Sistas worldwide who participated in this year's Movember campaign. Here in Canada, enthusiasm was on display in many forms, from spirited move challenges like 24-hour runs and epic host events like Suits & Staches in Toronto, to the first ever online host event of 24-hour gaming streams with EA Sports and over 60,000 official moustaches.
The Parking Lot Prostate Exam Project #TalkProstate
To stimulate public discussion about prostate cancer and the importance of early detection, Prostate Cancer Canada teamed up with FCB Canada and CFL legend Damon Allen during Prostate Cancer Awareness Month to help get a serious message across through a fun campaign.
Interpreting the study on early prostate cancer survival with Urologist and prostate cancer expert, Dr. Fred Saad
Toronto, ON – September 19, 2016: A study published last week in the New England Journal of Medicine followed men with localized (contained to the prostate) prostate cancer for 10 years as they underwent one of three randomized treatment streams has since been widely reported on. Notably, many of the headlines touched upon the same reassuring conclusion: whether participants were treated with radiation therapy, had their prostates removed altogether, or were simply monitored using Prostate-Specific Antigen (PSA) tests, survival after ten years was the same at 99 per cent.